Form 4: Theravance Biopharma Director Jeremy T. Grant Reports Share Option Grant and Disposal of Shares

Sentiment:

SEC Form 4 Filing


Director Jeremy T. Grant reports acquisition of share options and disposal of ordinary shares in Theravance Biopharma, Inc.

Summary

  • On May 19, 2025, Jeremy T. Grant, a director of Theravance Biopharma, Inc., reported transactions involving the company's securities.
  • Grant acquired 24,258 share options with an exercise price of $9.39, exercisable from May 18, 2035.
  • He also disposed of 10,649 ordinary shares.
  • Following these transactions, Grant beneficially owns 32,954 ordinary shares and 24,258 share options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The disposal of shares is balanced by the acquisition of options.

Positives

  • The acquisition of share options by a director may indicate confidence in the company's future performance.

Negatives

  • The disposal of 10,649 ordinary shares by the director could be interpreted negatively by some investors, although the reason for the disposal is not specified.

Risks

  • The document does not explicitly mention any risks.
  • However, any disposal of shares by a company insider could be perceived as a negative signal by the market.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

  • Insider trading disclosures are standard practice for publicly traded companies like Theravance Biopharma.
  • Similar filings are made by executives and directors at companies like Amgen, Gilead Sciences, and Biogen to report changes in their ownership positions.

Stakeholder Impact

  • Shareholders may react to the insider transactions, potentially influencing the stock price.

Key Dates

DateDescription
05/19/2025Date of transaction: acquisition of share options and disposal of ordinary shares.
05/18/2035Share options exercisable from this date.
05/21/2025Date of signature on the Form 4 filing.

Keywords

Theravance Biopharma, Director, Share Options, Ordinary Shares, Beneficial Ownership, Form 4, TBPH, Grant Jeremy T

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.